Nick James also on @Prof-Nick-James.bsky.social
@Prof_Nick_James
Professor of Prostate and Bladder Cancer Research. Interests: from novel diagnostics to care of advanced disease and novel trial design
Could adding metformin to standard treatment help reduce side effects in men with advanced #ProstateCancer? A team led by Prof Noel Clarke @UoM_DCS, @TheChristieNHS, and @SalfordUrology share exciting new findings in @TheLancetOncol. Grab a ☕ and read: doi.org/10.1016/S1470-…
Congrats @Prof_Nick_James & team👉@asco #ASCO25 👉a prognostic digital pathology based AI score (@arteraAI) identifies pts with clinically high-risk #prostatecancer (non metastatic) 👉likely to benefit most from adding abiraterone to SOC @OncoAlert @urotoday @PCFnews
In the context of #MIBC, is #TURBT still needed? 🔍 Some experts propose replacing it with sample biopsy. Ready for the debate? Join the #UROwebinar and find out more from experts @paolo_gontero, @ParamMariappan, @Prof_Nick_James, and @amassonlecomte👇 webinars.uroweb.org/EAU/webinars/1…
Interesting, but needs to be benchmarked against schedules that include RT. Good long term function and durable high bladder preservation rates
RETAIN-2 study shows promise for #BladderCancer preservation. @GhataliaPooja @FoxChaseCancer joins @UroDocAsh @MDAndersonNews to discuss the results and emphasizes that these results exceed previous chemo-immunotherapy combinations and highlight the importance of bladder…
@AshwinUrol presented metabolic outcomes data from the #STAMPEDE metformin trial demonstrating that the addition of metformin to SOC mitigates adverse metabolic effects of ADT - this work was featured in the Best of #EAU25 ⭐️ session
Very proud to collect this award on behalf of the huge team that makes up the STAMPEDE trial @MRCCTU staff, at least 3000 site staff and of course 12000 patients and their families. #teamscience
Our third #NIHRImpactPrizes established investigator winner 🏆 is the STAMPEDE trial, for their multi arm platform trial to assess 10 different treatment approaches in men with advanced prostate cancer, leading to improvements in survival. Congratulations! The award was collected…
Our third #NIHRImpactPrizes established investigator winner 🏆 is the STAMPEDE trial, for their multi arm platform trial to assess 10 different treatment approaches in men with advanced prostate cancer, leading to improvements in survival. Congratulations! The award was collected…
Really interesting chat - how to design trials with injectables a challenging area. Also how to deal with issues like replication competent viruses in the COVID 19 conspiracy era touched upon!
🎙 New Trials and Tribulations Podcast Episode with Prof Kevin Harrington, Head of Radiotherapy& Imaging @ICR_London and Consultant Oncologist @royalmarsdenNHS! We delve into biological agents and clinical trials 🎧 open.spotify.com/episode/27WtMQ… @Prof_Nick_James @Hoda_Aty
🎙 New Trials and Tribulations Podcast Episode with Prof Kevin Harrington, Head of Radiotherapy& Imaging @ICR_London and Consultant Oncologist @royalmarsdenNHS! We delve into biological agents and clinical trials 🎧 open.spotify.com/episode/27WtMQ… @Prof_Nick_James @Hoda_Aty
Our RADIO trial safety data on chemoRt- immunotherapy with durvalumab for muscle invasive bladder cancer from GU ASCO. In a nutshell - its safe and deliverable @CRCTU @ICR_London @VJOncology vjoncology.com/video/fkxflf2o…
Two interviews on the latest STAMPEDE data on topical oestrogen in place of standard ADT @ICR_London @MRCCTU Teh second interview: Published by @VJOncology vjoncology.com/video/n0urhrxc…
Two interviews on the latest STAMPEDE data on topical oestrogen in place of standard ADT @ICR_London @MRCCTU Published by @VJOncology vjoncology.com/video/g0h6gyle…
Great to see the #STAMPEDE trial shortlisted for the @NIHRresearch Impact Prize 2025! 🏆 nihr.ac.uk/about-us/our-i… @MRCCTU @Prof_Nick_James @MaxParmarMRCUCL @AttardLab @GUresearch_MCR @TheChristieNHS @MCRCnews
The wait is over! The NIHR Impact Prizes shortlist is here.🎉 Out of 136 outstanding entries, we’ll be celebrating a handful of researchers & teams whose work is transforming lives & driving economic growth.🌟 Winners will be revealed on 20 March. Stay tuned! Who are the…
#Metformin study reveals weight management benefits for ADT therapy. @Silke_Gillessen and @neerajaiims discuss the results of the #STAMPEDE trial's metformin arm. The phase 3 trial evaluates the addition of metformin to ADT in patients with #mHSPC. #FullVideo on UroToday >…
Really powerful speech. We need to listen and act.
French senator perfectly describes the Trump situation.
Latest from #STAMPEDE - intensified AR targeting drives increased prevalence of AR mutations at progression compared to monotherapy patient samples jamanetwork.com/journals/jamao… @MRCCTU @ICR_London @AttardLab
Has indeed been a great meeting!
#APCCCD @APCCC_Lugano Great times with the incredible @Prof_Nick_James and @piet_ost Wonderful debates, discussions of major trial gaps, learning the strengths weaknesses of each of our country’s health systems, and now I have a new podcast to listen to from @Prof_Nick_James.…
#APCCCD @APCCC_Lugano Great times with the incredible @Prof_Nick_James and @piet_ost Wonderful debates, discussions of major trial gaps, learning the strengths weaknesses of each of our country’s health systems, and now I have a new podcast to listen to from @Prof_Nick_James.…
Hormone intensification at ADT initiation increases AR alterations at progression! 🧬 In STAMPEDE, AR gene alterations were significantly higher in patients receiving ADT + enzalutamide/abiraterone vs ADT alone! @AttardLab @Prof_Nick_James @JAMAOnc @APCCC_Lugano @OncoAlert…